30% off. Use code SUMMERSALE30 at checkout for 30% off for 12 months on Plus, Pro and Premium subscriptions. Subscribe now
United States Pharmaceuticals

Bristol-Myers Squibb Co (BMY)

Track

Over the last 90 days, Bristol-Myers Squibb Co. has seen 3 insider transactions totaling $3.7 million in sales. Notably, EVP & CFO David V. Elkins made multiple planned and proposed sales. The company's stock has experienced a 2.8% decrease in the past 90 days. The last earnings report exceeded expectations by 13.9%.
Stock chart
Ticker: BMY Exchange: NYS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Top insiders
Trades
Elkins David V
EVP, Chief Financial Officer
3 sales — total 3,700,661 USD
Planned sale 1 Apr 2026
Value US$2,317,810.33 | Price 107.65 | Shares 56,268
Planned sale 1 Apr 2026
Value US$4,114,765.62 | Price 172.15 | Shares 73,125
Proposed sale 1 Apr 2026
Value US$1,850,644.69 | Price 61.69 | Shares 30,000
Planned sale 2 Sep 2025
Value US$878,457.40 | Price 121.83 | Shares 92,529
Proposed sale 2 Sep 2025
Value US$2,027,270.74 | Price 190.80 | Shares 28,900
Sale 2 Aug 2025
Value US$16,718.94 | Price 44.23 | Shares 378
Sale 9 May 2025
Value US$3,701.83 | Price 38.01 | Shares 97
Buy 25 Apr 2025
Value US$202,215.00 | Price 47.58 | Shares 4,250
Buy 20 Feb 2025
Value US$110,096.00 | Price 55.05 | Shares 2,000
Buy 14 Feb 2025
Value US$99,999.97 | Price 54.84 | Shares 1,823
Sale 4 Nov 2024
Value US$38,930.50 | Price 55.62 | Shares 700
Proposed sale 4 Nov 2024
Value US$38,930.50 | Price 55.62 | Shares 700
Buy 1 Nov 2024
Value US$100,055.25 | Price 54.68 | Shares 1,830
Buy 5 Dec 2023
Value US$99,560.00 | Price 49.78 | Shares 2,000
Buy 28 Nov 2023
Value US$150,049.06 | Price 48.86 | Shares 3,071
Buy 20 Nov 2023
Value US$423,385.00 | Price 49.81 | Shares 8,500
Sale 24 Aug 2023
Value US$1,101,642.50 | Price 61.25 | Shares 17,986
Proposed sale 24 Aug 2023
Value US$1,101,652.97 | Price 61.25 | Shares 17,986
Sale 3 Aug 2023
Value US$44,754.48 | Price 61.14 | Shares 732
Proposed sale 3 Aug 2023
Value US$44,756.44 | Price 61.14 | Shares 732
Sale 3 May 2023
Value US$3,378,818.10 | Price 67.06 | Shares 50,385
Proposed sale 3 May 2023
Value US$3,378,940.88 | Price 67.06 | Shares 50,385
Sale 6 Feb 2023
Value US$835,258.27 | Price 74.69 | Shares 11,183
Sale 6 Feb 2023
Value US$17,916,000.00 | Price 74.65 | Shares 240,000
Sale 9 Nov 2022
Value US$1,307,312.50 | Price 80.45 | Shares 16,250
Sale 7 Nov 2022
Value US$3,621,380.80 | Price 78.88 | Shares 45,910
Planned sale 20 Sep 2022
Value US$1,742,750.00 | Price 69.71 | Shares 25,000
Sale 15 Sep 2022
Value US$3,592,000.00 | Price 71.84 | Shares 50,000
Sale 14 Sep 2022
Value US$1,768,750.00 | Price 70.75 | Shares 25,000
Sale 13 Sep 2022
Value US$7,410,666.79 | Price 71.29 | Shares 103,951
Sale 13 Sep 2022
Value US$2,140,500.00 | Price 71.35 | Shares 30,000
Sale 13 Jun 2022
Value US$2,221,200.00 | Price 74.04 | Shares 30,000
Sale 6 Jun 2022
Value US$4,867,850.00 | Price 74.89 | Shares 65,000
Planned sale 21 Mar 2022
Value US$1,788,000.00 | Price 71.52 | Shares 25,000
Sale 16 Mar 2022
Value US$2,992,674.44 | Price 69.23 | Shares 43,228
Sale 16 Mar 2022
Value US$2,170,298.37 | Price 69.27 | Shares 31,331
Sale 14 Mar 2022
Value US$455,095.52 | Price 69.20 | Shares 6,577
Sale 14 Mar 2022
Value US$2,043,525.80 | Price 69.20 | Shares 29,532
Sale 24 Feb 2022
Value US$2,010,000.00 | Price 67.00 | Shares 30,000
Sale 16 Dec 2021
Value US$812,069.00 | Price 61.99 | Shares 13,100
Sale 16 Dec 2021
Value US$384,183.03 | Price 61.99 | Shares 6,198
Sale 24 Nov 2021
Value US$987,732.76 | Price 56.92 | Shares 17,353
Sale 23 Nov 2021
Value US$886,072.46 | Price 57.47 | Shares 15,418
Sale 22 Nov 2021
Value US$1,049,812.71 | Price 57.17 | Shares 18,363
Sale 30 Jul 2021
Value US$9,575,656.24 | Price 68.08 | Shares 140,653
Sale 30 Jul 2021
Value US$1,206,497.40 | Price 68.01 | Shares 17,740
Sale 10 May 2021
Value US$978,750.00 | Price 65.25 | Shares 15,000
Sale 5 May 2021
Value US$1,963,802.34 | Price 64.29 | Shares 30,546
Sale 5 May 2021
Value US$200,270.99 | Price 64.21 | Shares 3,119
Planned sale 22 Mar 2021
Value US$1,555,000.00 | Price 62.20 | Shares 25,000
Sale 25 Nov 2020
Value US$190.50 | Price 63.50 | Shares 3
Sale 24 Nov 2020
Value US$57,051.00 | Price 63.39 | Shares 900
Sale 24 Nov 2020
Value US$1,255,000.00 | Price 62.75 | Shares 20,000
Sale 23 Nov 2020
Value US$823,244.14 | Price 61.34 | Shares 13,421
Sale 19 Nov 2020
Value US$2,882,305.72 | Price 61.31 | Shares 47,012
Sale 19 Nov 2020
Value US$647,963.75 | Price 61.25 | Shares 10,579
Sale 31 Aug 2020
Value US$2,497,968.00 | Price 62.70 | Shares 39,840
Sale 17 Aug 2020
Value US$340,928.00 | Price 64.00 | Shares 5,327
Sale 13 Aug 2020
Value US$8,943,400.80 | Price 63.24 | Shares 141,420
Buy 15 Jun 2020
Value US$499,983.00 | Price 54.50 | Shares 9,174
Sale 22 May 2020
Value US$195,232.00 | Price 61.01 | Shares 3,200
Sale 19 May 2020
Value US$1,567,000.00 | Price 62.68 | Shares 25,000
Sale 4 Mar 2020
Value US$964,263.05 | Price 61.01 | Shares 15,805
Sale 2 Mar 2020
Value US$5,108,221.72 | Price 60.59 | Shares 84,308
Sale 5 Dec 2019
Value US$102,329.40 | Price 58.81 | Shares 1,740
Buy 4 Dec 2019
Value US$5,183.20 | Price 58.90 | Shares 88
Sale 5 Nov 2019
Value US$849,900.00 | Price 56.66 | Shares 15,000
Sale 5 Nov 2019
Value US$1,414,000.00 | Price 56.56 | Shares 25,000
Buy 31 Jul 2019
Value US$491,920.00 | Price 44.72 | Shares 11,000
Sale 16 May 2019
Value US$145,771.40 | Price 47.56 | Shares 3,065
Buy 16 May 2019
Value US$236,440.00 | Price 47.29 | Shares 5,000
Buy 30 Apr 2018
Value US$249,948.00 | Price 52.40 | Shares 4,770
Buy 15 Dec 2017
Value US$249,187.20 | Price 62.30 | Shares 4,000
Sale 12 Dec 2017
Value US$335,172.00 | Price 63.24 | Shares 5,300
Sale 4 Dec 2017
Value US$9,922,601.34 | Price 63.37 | Shares 156,582
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-04-02 2026-04-01 PlS Planned sale
1.2
Elkins David V

EVP, Chief Financial Officer

Officer
56,268 +39.0%
107.65
US$2,317,810 		56,268 +39.0% 107.65 US$2,317,810
2026-04-02 2026-04-01 PlS Planned sale
1.2
Elkins David V

EVP, Chief Financial Officer

Officer
73,125 +13.1%
172.15
US$4,114,766 		73,125 +13.1% 172.15 US$4,114,766
2026-04-01 2026-04-01 PrS Proposed sale
1.2
Elkins David V

Officer

Officer
74,032
345.39
US$3,170,906 		74,032 345.39 US$3,170,906
2025-09-03 2025-09-02 PlS Planned sale
1.2
Elkins David V

EVP, Chief Financial Officer

Officer
56,000 -25.1%
47.33
US$2,650,480 		56,000 -25.1% 47.33 US$2,650,480
2025-09-02 2025-09-02 PrS Proposed sale
1.2
Elkins David V

Officer

Officer
56,000
47.30
US$2,648,800 		56,000 47.30 US$2,648,800
2025-08-05 2025-08-02 S Sale
0.8
Short Bartie Wendy

EVP, Corporate Affairs

Officer
378 -6.9%
44.23
US$16,719 		378 -6.9% 44.23 US$16,719
2025-05-13 2025-05-09 S Sale
Hickey Benjamin

President, RayzeBio Org.

Officer
97 -100.0%
38.01
US$3,702 		97 -100.0% 38.01 US$3,702
2025-04-29 2025-04-25 B Purchase
2.9
Hirawat Samit

EVP,Chief Med.Offr.,Drug Dev.

Officer
4,250 +5.4%
47.58
US$202,215 		4,250 +5.4% 47.58 US$202,215
2025-02-21 2025-02-20 B Purchase
2.0
BOERNER CHRISTOPHER S.

Chief Executive Officer

Executive Director
2,000 +1.9%
55.05
US$110,096 		2,000 +1.9% 55.05 US$110,096
2025-02-19 2025-02-14 B Purchase
2.9
Hirawat Samit

EVP,Chief Med.Offr.,Drug Dev.

Officer
1,823 +2.9%
54.84
US$100,000 		1,823 +2.9% 54.84 US$100,000
2024-11-05 2024-11-04 S Sale
0.9
Holzer Phil M

SVP and Controller

Officer
700 -5.6%
55.62
US$38,930 		700 -5.6% 55.62 US$38,930
2024-11-04 2024-11-04 PrS Proposed sale
0.9
Holzer Phil M

Officer

Officer
700
55.62
US$38,930 		700 55.62 US$38,930
2024-11-05 2024-11-01 B Purchase
2.9
Hirawat Samit

EVP,Chief Med.Offr.,Drug Dev.

Officer
1,830 +3.0%
54.68
US$100,055 		1,830 +3.0% 54.68 US$100,055
2023-12-07 2023-12-05 B Purchase
2.0
BOERNER CHRISTOPHER S.

Chief Executive Officer

Officer
2,000 +2.5%
49.78
US$99,560 		2,000 +2.5% 49.78 US$99,560
2023-11-30 2023-11-28 B Purchase
2.0
BOERNER CHRISTOPHER S.

Chief Executive Officer

Officer
3,071 +4.0%
48.86
US$150,049 		3,071 +4.0% 48.86 US$150,049
2023-11-21 2023-11-20 B Purchase
3.4
Samuels Theodore R. II
Non-Executive Director
8,500 +31.5%
49.81
US$423,385 		8,500 +31.5% 49.81 US$423,385
2023-08-28 2023-08-24 S Sale
3.2
Powell Ann

EVP, Chief Human Resources

Officer
17,986 -39.2%
61.25
US$1,101,642 		17,986 -39.2% 61.25 US$1,101,642
2023-08-24 2023-08-24 PrS Proposed sale
3.2
Powell Ann

Officer

Officer
17,986
61.25
US$1,101,653 		17,986 61.25 US$1,101,653
2023-08-07 2023-08-03 S Sale
2.9
Plenge Robert M

EVP, Chief Research Officer

Officer
732 -10.0%
61.14
US$44,754 		732 -10.0% 61.14 US$44,754
2023-08-03 2023-08-03 PrS Proposed sale
2.9
Plenge Robert M

Officer

Officer
732
61.14
US$44,756 		732 61.14 US$44,756
2023-05-04 2023-05-03 S Sale
3.3
VESSEY RUPERT

EVP & President, Research

Officer
50,385 -51.3%
67.06
US$3,378,818 		50,385 -51.3% 67.06 US$3,378,818
2023-05-03 2023-05-03 PrS Proposed sale
3.3
VESSEY RUPERT

Officer

Officer
50,385
67.06
US$3,378,941 		50,385 67.06 US$3,378,941
2023-02-08 2023-02-06 S Sale
3.2
Powell Ann

EVP, Chief Human Resources

Officer
11,183 -32.7%
74.69
US$835,258 		11,183 -32.7% 74.69 US$835,258
2023-02-08 2023-02-06 S Sale
3.5
Caforio Giovanni

Board Chair and CEO

Executive Director
240,000 -50.4%
74.65
US$17,916,000 		240,000 -50.4% 74.65 US$17,916,000
2022-11-14 2022-11-09 S Sale
3.2
Powell Ann

EVP, Chief Human Resources

Officer
16,250 -32.2%
80.45
US$1,307,312 		16,250 -32.2% 80.45 US$1,307,312
2022-11-09 2022-11-07 S Sale
3.3
VESSEY RUPERT

EVP, Research & Early Dev.

Officer
45,910 -44.6%
78.88
US$3,621,381 		45,910 -44.6% 78.88 US$3,621,381
2022-09-22 2022-09-20 PlS Planned sale
3.5
Caforio Giovanni

Board Chair and CEO

Executive Director
25,000 -5.0%
69.71
US$1,742,750 		25,000 -5.0% 69.71 US$1,742,750
2022-09-16 2022-09-15 S Sale
3.5
Caforio Giovanni

Board Chair and CEO

Executive Director
50,000 -9.1%
71.84
US$3,592,000 		50,000 -9.1% 71.84 US$3,592,000
2022-09-15 2022-09-14 S Sale
3.2
Powell Ann

EVP, Chief Human Resources

Officer
25,000 -33.1%
70.75
US$1,768,750 		25,000 -33.1% 70.75 US$1,768,750
2022-09-15 2022-09-13 S Sale
1.2
Elkins David V

EVP, Chief Financial Officer

Officer
103,951 -46.5%
71.29
US$7,410,667 		103,951 -46.5% 71.29 US$7,410,667
2022-09-15 2022-09-13 S Sale
1.2
Elkins David V

EVP, Chief Financial Officer

Officer
30,000 -23.0%
71.35
US$2,140,500 		30,000 -23.0% 71.35 US$2,140,500
2022-06-14 2022-06-13 S Sale
3.5
Caforio Giovanni

Board Chair and CEO

Executive Director
30,000 -5.2%
74.04
US$2,221,200 		30,000 -5.2% 74.04 US$2,221,200
2022-06-07 2022-06-06 S Sale
2.8
LEUNG SANDRA

EVP, General Counsel

Officer
65,000 -17.4%
74.89
US$4,867,850 		65,000 -17.4% 74.89 US$4,867,850
2022-03-23 2022-03-21 PlS Planned sale
3.5
Caforio Giovanni

Board Chair and CEO

Executive Director
25,000 -4.1%
71.52
US$1,788,000 		25,000 -4.1% 71.52 US$1,788,000
2022-03-18 2022-03-16 S Sale
3.3
VESSEY RUPERT

EVP, Research & Early Dev.

Officer
43,228 -46.2%
69.23
US$2,992,674 		43,228 -46.2% 69.23 US$2,992,674
2022-03-18 2022-03-16 S Sale
3.3
VESSEY RUPERT

EVP, Research & Early Dev.

Officer
31,331 -40.4%
69.27
US$2,170,298 		31,331 -40.4% 69.27 US$2,170,298
2022-03-16 2022-03-14 S Sale
1.6
Santiago Karen Murphy

SVP & Controller

Officer
6,577 -28.3%
69.20
US$455,096 		6,577 -28.3% 69.20 US$455,096
2022-03-16 2022-03-14 S Sale
2.0
BOERNER CHRISTOPHER S.

EVP, Chief Commercial Officer

Officer
29,532 -41.3%
69.20
US$2,043,526 		29,532 -41.3% 69.20 US$2,043,526
2022-02-28 2022-02-24 S Sale
3.5
Caforio Giovanni

Board Chair and CEO

Executive Director
30,000 -6.2%
67.00
US$2,010,000 		30,000 -6.2% 67.00 US$2,010,000
2021-12-17 2021-12-16 S Sale
3.3
VESSEY RUPERT

EVP, Research & Early Dev.

Officer
13,100 -29.1%
61.99
US$812,069 		13,100 -29.1% 61.99 US$812,069
2021-12-17 2021-12-16 S Sale
3.3
VESSEY RUPERT

EVP, Research & Early Dev.

Officer
6,198 -12.1%
61.99
US$384,183 		6,198 -12.1% 61.99 US$384,183
2021-11-24 2021-11-24 S Sale
1.7
von Autenried Paul

EVP, Chief Information Officer

Officer
17,353 -21.5%
56.92
US$987,733 		17,353 -21.5% 56.92 US$987,733
2021-11-24 2021-11-23 S Sale
1.7
von Autenried Paul

EVP, Chief Information Officer

Officer
15,418 -16.0%
57.47
US$886,072 		15,418 -16.0% 57.47 US$886,072
2021-11-24 2021-11-22 S Sale
1.7
von Autenried Paul

EVP, Chief Information Officer

Officer
18,363 -16.0%
57.17
US$1,049,813 		18,363 -16.0% 57.17 US$1,049,813
2021-08-03 2021-07-30 S Sale
3.3
VESSEY RUPERT

EVP, Research & Early Dev.

Officer
140,653 -75.0%
68.08
US$9,575,656 		140,653 -75.0% 68.08 US$9,575,656
2021-08-03 2021-07-30 S Sale
3.3
VESSEY RUPERT

EVP, Research & Early Dev.

Officer
17,740 -32.6%
68.01
US$1,206,497 		17,740 -32.6% 68.01 US$1,206,497
2021-05-11 2021-05-10 S Sale
2.4
Schmukler Louis S

EVP,Pres.,Glob.Prod. & Supply

Officer
15,000 -31.9%
65.25
US$978,750 		15,000 -31.9% 65.25 US$978,750
2021-05-07 2021-05-05 S Sale
3.3
VESSEY RUPERT

EVP, Research & Early Dev.

Officer
30,546 -40.4%
64.29
US$1,963,802 		30,546 -40.4% 64.29 US$1,963,802
2021-05-07 2021-05-05 S Sale
3.0
Dubow Adam

SVP,ChiefCompliance&EthicsOff.

Officer
3,119 -16.1%
64.21
US$200,271 		3,119 -16.1% 64.21 US$200,271
2021-03-24 2021-03-22 PlS Planned sale
3.5
Caforio Giovanni

Chairman and CEO

Executive Director
25,000 -4.5%
62.20
US$1,555,000 		25,000 -4.5% 62.20 US$1,555,000
2020-11-30 2020-11-25 S Sale
1.7
von Autenried Paul

EVP, Chief Information Officer

Officer
3 -0.0%
63.50
US$190 		3 -0.0% 63.50 US$190
2020-11-25 2020-11-24 S Sale
3.0
Dubow Adam

SVP,ChiefCompliance&EthicsOff.

Officer
900 -5.6%
63.39
US$57,051 		900 -5.6% 63.39 US$57,051
2020-11-25 2020-11-24 S Sale
1.7
von Autenried Paul

EVP, Chief Information Officer

Officer
20,000 -13.6%
62.75
US$1,255,000 		20,000 -13.6% 62.75 US$1,255,000
2020-11-25 2020-11-23 S Sale
3.3
VESSEY RUPERT

EVP, Research & Early Dev.

Officer
13,421 -26.1%
61.34
US$823,244 		13,421 -26.1% 61.34 US$823,244
2020-11-23 2020-11-19 S Sale
3.3
VESSEY RUPERT

EVP, Research & Early Dev.

Officer
47,012 -47.8%
61.31
US$2,882,306 		47,012 -47.8% 61.31 US$2,882,306
2020-11-23 2020-11-19 S Sale
3.3
VESSEY RUPERT

EVP, Research & Early Dev.

Officer
10,579 -18.7%
61.25
US$647,964 		10,579 -18.7% 61.25 US$647,964
2020-09-02 2020-08-31 S Sale
3.5
Caforio Giovanni

Chairman and CEO

Executive Director
39,840 -8.2%
62.70
US$2,497,968 		39,840 -8.2% 62.70 US$2,497,968
2020-08-19 2020-08-17 S Sale
2.3
Eid Joseph

SVP,Head Glob. Medical Affairs

Officer
5,327 -67.8%
64.00
US$340,928 		5,327 -67.8% 64.00 US$340,928
2020-08-17 2020-08-13 S Sale
2.8
LEUNG SANDRA

EVP, General Counsel

Officer
141,420 -24.6%
63.24
US$8,943,401 		141,420 -24.6% 63.24 US$8,943,401
2020-06-16 2020-06-15 B Purchase
3.6
Paliwal Dinesh C
Non-Executive Director
9,174 +70.9%
54.50
US$499,983 		9,174 +70.9% 54.50 US$499,983
2020-05-26 2020-05-22 S Sale
3.0
Dubow Adam

SVP,ChiefCompliance&EthicsOff.

Officer
3,200 -16.6%
61.01
US$195,232 		3,200 -16.6% 61.01 US$195,232
2020-05-21 2020-05-19 S Sale
2.4
Schmukler Louis S

EVP,Pres.,Glob.Prod. & Supply

Officer
25,000 -48.3%
62.68
US$1,567,000 		25,000 -48.3% 62.68 US$1,567,000
2020-03-06 2020-03-04 S Sale
2.3
Elicker John E

EVP, Investor Relations

Officer
15,805 -21.2%
61.01
US$964,263 		15,805 -21.2% 61.01 US$964,263
2020-03-04 2020-03-02 S Sale
3.3
VESSEY RUPERT

Pres., Research & Early Dev.

Officer
84,308 -63.6%
60.59
US$5,108,222 		84,308 -63.6% 60.59 US$5,108,222
2019-12-09 2019-12-05 S Sale Dubow Adam

Chief Compliance & Ethics Offi

Officer
1,740 -9.9%
58.81
US$102,329 		1,740 -9.9% 58.81 US$102,329
2020-06-09 2019-12-04 B Purchase
3.0
BONNEY MICHAEL W
Non-Executive Director
88 +1.2%
58.90
US$5,183 		88 +1.2% 58.90 US$5,183
2019-11-06 2019-11-05 S Sale Elicker John E

SVP, Public Affairs & IR

Officer
15,000 -16.8%
56.66
US$849,900 		15,000 -16.8% 56.66 US$849,900
2019-11-06 2019-11-05 S Sale Schmukler Louis S

Pres., Global Mfg. & Supply

Officer
25,000 -43.9%
56.56
US$1,414,000 		25,000 -43.9% 56.56 US$1,414,000
2019-08-01 2019-07-31 B Purchase BERTOLINI ROBERT J Non-Executive Director
11,000 +2770.8%
44.72
US$491,920 		11,000 +2770.8% 44.72 US$491,920
2019-05-20 2019-05-16 S Sale
1.6
Santiago Karen Murphy

Controller
3,065 -50.0%
47.56
US$145,771 		3,065 -50.0% 47.56 US$145,771
2019-05-20 2019-05-16 B Purchase
3.4
Samuels Theodore R. II
5,000 +22.7%
47.29
US$236,440 		5,000 +22.7% 47.29 US$236,440
2018-05-02 2018-04-30 B Purchase Paliwal Dinesh C Non-Executive Director
4,770 +146.5%
52.40
US$249,948 		4,770 +146.5% 52.40 US$249,948
2017-12-18 2017-12-15 B Purchase Samuels Theodore R. II
4,000 +22.2%
62.30
US$249,187 		4,000 +22.2% 62.30 US$249,187
2017-12-13 2017-12-12 S Sale Lynch Thomas J. Jr.

EVP & Chief Scientific Officer
5,300 -36.4%
63.24
US$335,172 		5,300 -36.4% 63.24 US$335,172
2017-12-05 2017-12-04 S Sale LEUNG SANDRA

EVP, General Counsel
156,582 -26.8%
63.37
US$9,922,601 		156,582 -26.8% 63.37 US$9,922,601
Explore more

More insider trading research around Bristol-Myers Squibb Co

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Pharmaceuticals companies with insider activity
Insider trading in North America
Insider trades in S&P 500